Vasculitis & polymyalgia rheumatica
Aneurysmal Disease in Patients With Takayasu Arteritis
Authors' conclusion
Aneurysmal disease was found in a significant proportion of patients with TA.
Study context
- Population
- Patients with takayasu arteritis (TA) followed at the Mount Sinai Hospital Vasculitis Clinic in Toronto, Canada; diagnosis based on clinical findings and/or 1990 ACR classification criteria
- Participants
- 74 patients
- Exposure
- TA with aneurysmal disease vs TA without aneurysmal disease
- Aneurysmal diseasen = 23
- Outcome
- Main characteristics of aneurysmal disease in TA
Methodological detailsmonocentric
- Monocentric
Main finding
As reported in the abstract
Aneurysmal disease at any time
Aneurysmal disease
31%
23
Observational data: associations, not effects.
Further findings
Disease duration in patients with aneurysmal disease
- Median disease duration, years (IQR 7.0-19.0)
- 9.0
Clinical features with vs without aneurysmal disease
- Prior hypertension more common
- P = 0.02
- Fever more common
- P = 0.04
- Seizure disorders more common
- P = 0.03
- Limb claudication less frequent
- P = 0.01
Persistent and/or new aneurysms at follow-up
- Patients with persistent and/or new aneurysms
- 22/23
Aneurysm location
- Thoracic aorta (most common)
- 13/22
- Abdominal aorta
- 8/22
- Subclavian artery
- 7/22
- Carotid artery
- 6/22
Aortic valve regurgitation, more frequent with aneurysms
- With vs without aneurysms
- 9/23 vs 3/48; P = 0.001
Treatment in patients with aneurysmal disease
- Treated with GC
- 21
- GC duration, median years (IQR 3.7-8.1)
- 6.1
- Infliximab, used more often (P = 0.04)
- 7/23
- Tocilizumab, received by only (P = 0.01)
- 4
- MTX, AZA and LEF repeatedly used
Relapses, more frequent with aneurysms
- Median relapses, with vs without aneurysms
- 2.0 [IQR 0.0-4.0] vs 1.0 [IQR 0.0-2.0], P = 0.04
Original publication
Aneurysmal Disease in Patients With Takayasu Arteritis. J Rheumatol. Published 15 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →